The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The deal signals a clear push to expand access to care in underserved regions
Subscribe To Our Newsletter & Stay Updated
